CompletedPhase 3NCT04856891

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis

Studying Eosinophilic gastroenteritis

Last synced from ClinicalTrials.gov May 17, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Allakos Inc.
Principal Investigator: Craig Paterson, MD, L. Ac
Allakos Inc.
Intervention: AK002(drug)
Enrollment: 94 enrolled
Eligibility: 18-80 years · All sexes
Timeline: 2021 – 2023

Study locations (30)

Allakos Investigational Site, Birmingham, Alabama, United States
Allakos Investigational Site, Gilbert, Arizona, United States
Allakos Investigational Site, Chula Vista, California, United States
Allakos Investigational Site, Lomita, California, United States
Allakos Investigational Site, Wheat Ridge, Colorado, United States
Allakos Investigational Site, Bristol, Connecticut, United States
Allakos Investigational Site, Hamden, Connecticut, United States
Allakos Investigational Site, Brandon, Florida, United States
Allakos Investigational Site, Edgewater, Florida, United States
Allakos Investigational Site, Jacksonville, Florida, United States
Allakos Investigational Site, Kissimmee, Florida, United States
Allakos Investigational Site, Lakewood Rch, Florida, United States
Allakos Investigational Site, New Port Richey, Florida, United States
Allakos Investigational Site, Ponte Vedra, Florida, United States
Allakos Investigational Site, Crowley, Louisiana, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04856891 on ClinicalTrials.gov

Other trials for Eosinophilic gastroenteritis

Additional recruiting or active studies for the same condition.

See all trials for Eosinophilic gastroenteritis →

← Back to all trials